LEP Biomedical

Voting for the Spark Crowdfunding Top 100 Most Ambitious Companies in Ireland competition is now open, and it’s your chance to support some incredible Irish innovations. Voting closes at 1pm on Monday, March 31st. Royal College of Surgeons in Ireland (RCSI) spin-outs LEP Biomedical, Pumpinheart, and Vertigenius™️ are among the companies vying for the top spot. You can cast your vote here: https://lnkd.in/dE-9ZuuM For more details on all the participating companies, check out the full list here: https://lnkd.in/ddK39x6s Make sure to vote before the deadline! #RCSIdiscover #EUinmyregion

Spark Crowdfunding is again delighted to announce that **IRELAND'S TOP 100 MOST AMBITIOUS COMPANIES** - JUST UNVEILED. Celebrating innovation, resilience, and the visionary spirit driving Ireland's business landscape. Discover the trailblazers shaping our future! Please **RE-POST**. https://lnkd.in/dvUsvbQr

Busy day yesterday with the excellent InterTradeIreland All Ireland #VC conference at Croke Park in the morning followed by Royal College of Surgeons in Ireland (RCSI) #Resesrch Day. This year's Research Day was especially enjoyable as team post-doc Adrián A. received an invention disclosure award from RCSI Innovation for his intellectual property enabling research! This work now further strengthens LEP Biomedical 's unique ocular drug delivery portfolio. Congrats Adrián A.! 👏

At Royal College of Surgeons in Ireland (RCSI), spinout companies are transforming cutting-edge research into real-world impact. From award-winning start-ups like Pumpinheart, Inthelia Therapeutics, LEP Biomedical, Tympulse Medical and Vertigenius™️, to securing funding, accelerator places, and industry recognition, 2024 was a standout year. These ventures are tackling global healthcare challenges through ground breaking medtech and biotech innovations. RCSI Spinout Development Manager Dr Conor MacCormack supports our company founders—helping them navigate funding, partnerships, and strategy to scale their innovations. The RCSI Office of Research and Innovation is committed to fostering entrepreneurship which is evident through initiatives like the MedTech Innovator competition, AIMS Summit, and Founder’s evening, providing a thriving ecosystem for start-ups to succeed. Looking ahead, we continue to champion entrepreneurs who turn research into impact. RCSI Innovation’s participation in KTBoost is co-funded by the Government of Ireland and the European Union through the ERDF Southern, Eastern & Midland Regional Programme 2021-2027 Knowledge Transfer Ireland (KTI) Enterprise Ireland Department of Enterprise, Trade and Employment Aoife Gallagher PhD, RTTP Derek John Seamus Browne Dawn McGlade #EUinmyregion #Entrepreneurship #YearInReview

👁️ 𝐆𝐥𝐚𝐮𝐜𝐨𝐦𝐚 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡 👁️ Following on from last weeks post about surgical and laser solutions for #glaucoma treatment, here are my featured technologies focused on drug release. It seems to be a common conversation in the market that drops aren't going anywhere, the solutions being used work at IOP lowering so the innovation will come from more effective and efficient methods of delivering pharmaceuticals to the eye. The iDose TR from Glaukos Corporation is an FDA approved, travoprost intracameral implant and it is 200 times smaller than a single drop of glaucoma medication. The anchored implant is designed to deliver drug therapy to the anterior chamber with 24/7 adherence to lower IOP without the burden of regular eye drops. 81% of patients have been shown to be completely free of the need for topical treatments after 12 months. SpyGlass Pharma, Inc. are taking an IOL mounted approach with the development of their drug-eluting pads combined with a single piece hydrophobic IOL implanted during routine cataract surgery. The drug-eluting pads then provide sustained release of bimatoprost over a 3 year period to provide IOP control without the need for drops. The Spyglass delivery platform is not yet approved by the FDA and the company is investigating the technologies uses for delivering other ophthalmic solutions. LEP Biomedical aim to make glaucoma drainage surgery 100% successful by improving patient recovery. The HyaGuard is designed to be inserted into the sub-conjunctival space to deliver controlled release of anti-inflammatory drugs to eliminate the need for self administered drops and therefore reducing the need for follow-up procedures.

Alan Hibbitts CEO LEP Biomedical feels a deep sense of appreciation and accomplishment following their win in the Medtech Startup 2024 Silver Award, proudly sponsored by Furthr 🏆✨ "The national startup award was a fantastic experience and a great opportunity to refine our business plan and pitch in front of industry leaders.” #yourstartupjourney #Startups #SUA2024 #NSA2024 #nationalstartupawards2024

LEP Biomedical takes Silver in Medtech Startup category at the National Startup Awards 2024 sponsored by Furthr Congratulations!!!!!       #yourstartupjourney #Startups #SUA2024 #NSA2024 #nationalstartupawards2024